Your browser doesn't support javascript.
loading
Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?
Tiotiu, Angelica; Poreaux, Claire; Poncet, Pascal; Senechal, Hélène; Schmutz, Jean-Luc.
Afiliación
  • Tiotiu A; University Hospital, Pulmonology Department, 54000 Nancy, France, University of Lorraine, EA 3450 DevAH, Development, Adaptation, Cardio-Respiratory Regulations and Motor Control, 54000 Nancy, France.
  • Poreaux C; University Hospital, Dermatology-Allergology Department, 54000 Nancy, France.
  • Poncet P; Pasteur Institute, Center for Innovation and Technological Research, 75000 Paris, France, Assistance Publique-Hôpitaux de Paris (AP-HP), Armand-Trousseau Children Hospital, Biochemistry Laboratory, Allergy and Environment Team, 75000 Paris, France.
  • Senechal H; Assistance Publique-Hôpitaux de Paris (AP-HP), Armand-Trousseau Children Hospital, Biochemistry Laboratory, Allergy and Environment Team, 75000 Paris, France.
  • Schmutz JL; University Hospital, Dermatology-Allergology Department, 54000 Nancy, France, University of Lorraine, 54000 Nancy, France.
Eur J Dermatol ; 29(1): 101-102, 2019 Feb 01.
Article en En | MEDLINE | ID: mdl-30734715

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Asma / Desensibilización Inmunológica / Antialérgicos / Dermatitis Atópica / Omalizumab Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Eur J Dermatol Asunto de la revista: DERMATOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Asma / Desensibilización Inmunológica / Antialérgicos / Dermatitis Atópica / Omalizumab Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Eur J Dermatol Asunto de la revista: DERMATOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Francia